SOLIGENIX, INC.
Tremor tracks 1 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- A key executive is leavingSince Jun 12, 2026+2.7
Trials
Key executives leaving
From the last 12 months of the company's SEC reports.
Jun 12, 2026
“Straube, MD, retired from his employment as Chief Medical Officer and Senior Vice President of Soligenix, Inc. (the “Company”) effective August 12, 2025 and entered into a one-year consulting agreement (the “Consulting Agreement”), pursuant to which Dr.”
Read the filing ↗
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.